UCLA study finds pre-surgery immunotherapy safe for pancreatic cancer patients

FHS
April 6, 2024
3:51 am

A pilot study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that for people with borderline resectable pancreatic cancer, administrating an immunotherapy drug in combination with chemotherapy before surgery is safe and may improve long-term outcomes.

Federal judge throws out two drugmaker IRA lawsuits in win for government

A New Jersey federal judge on Monday tossed cases brought by Johnson & Johnson and Bristol Myers Squibb against the Inflation Reduction Act, another victory

April 30, 2024

Including Polatuzumab Vedotin in First-Line DLBCL Treatment

The R-CHOP chemotherapy regimen — rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisone — has been the standard first-line therapy in diffuse large B-cell lymphoma

June 15, 2023

Controversial Gene Therapy Wins FDA Approval for Duchenne Muscular Dystrophy

The FDA granted accelerated approval to delandistrogene moxeparvovec (Elevidys), the first gene therapy for Duchenne muscular dystrophy, the agency announced Thursday. The adeno-associated virus-based gene

June 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.